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Abstract
Rrecent studies have highlighted a group of 4-repeat (4R) tauopathies that are characterised
neuropathologically by widespread, globular glial inclusions (GGIs). Tau immunohistochemistry
reveals 4R immunore-active globular oligodendroglial and astrocytic inclusions and the latter are
predominantly negative for Gallyas silver staining. These cases are associated with a range of
clinical presentations, which correlate with the severity and distribution of underlying tau
pathology and neurodegeneration. Their heterogeneous clinicopathological features combined
with their rarity and under-recognition have led to cases characterised by GGIs being described in
the literature using various and redundant terminologies. In this report, a group of
neuropathologists form a consensus on the terminology and classification of cases with GGIs.
After studying microscopic images from previously reported cases with suspected GGIs (n = 22),
this panel of neuropathologists with extensive experience in the diagnosis of neurodegenerative
diseases and a documented record of previous experience with at least one case with GGIs, agreed
that (1) GGIs were present in all the cases reviewed; (2) the morphology of globular astrocytic
inclusions was different to tufted astrocytes and finally that (3) the cases represented a number of
different neuropathological subtypes. They also agreed that the different morphological subtypes
are likely to be part of a spectrum of a distinct disease entity, for which they recommend that the
overarching term globular glial tauopathy (GGT) should be used. Type I cases typically present
with frontotemporal dementia, which correlates with the fronto-temporal distribution of pathology.
Type II cases are characterised by pyramidal features reflecting motor cortex involvement and
corticospinal tract degeneration. Type III cases can present with a combination of frontotemporal
dementia and motor neuron disease with fronto-temporal cortex, motor cortex and corticospinal
tract being severely affected. extrapyramidal features can be present in Type II and III cases and
significant degeneration of the white matter is a feature of all GGT subtypes. Improved detection
and classification will be necessary for the establishment of neuropathological and clinical
diagnostic research criteria in the future.
Introduction
Recent studies have highlighted a group of 4-repeat (4R) tauopathies that are characterised
neuropathologically by distinctive and widespread globular glial inclusions (GGIs). Such
cases can have a range of clinicopathological presentations, which has resulted in them
being described in the literature using various and redundant terminologies. In this paper, we
review the historical discovery of cases characterised by GGIs and highlight the difficulties
in classifying them in the past. With the aim of harmonising the terminologies that have
previously been used to describe such cases, a group of expert neuropathologists form a
consensus on their future classification and suggest suitable nomenclature. These
recommendations will hopefully improve the detection and correct classification of this
relatively rare and under-recognised form of 4R tauopathy.
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In 1998, Molina and colleagues described two types of “glial cytoplasmic inclusions”
(GCIs) in a temporal lobe biopsy obtained from a patient with moderate frontotemporal
atrophy and a clinical diagnosis of primary progressive aphasia. The first type was described
as “sickle or ring-shaped perinuclear inclusions” and the authors acknowledged that these
inclusions had some morphological similarities to GCIs observed in multiple system atrophy
(MSA). GCIs seen in MSA are consistently negative for phosphorylated-tau [4], although
those described by Molina et al. [18] were strongly immunoreactive for phosphorylated tau
epitopes. The second type of GCIs were described as “coarsely granular or patchy material
in the cell body and proximal portion of the cell processes” and were noted as being
reminiscent of the tau-positive glial inclusions of progressive supranuclear palsy (PSP).
Images of this particular type of GCI suggested they were morphologically heterogeneous
with some of the inclusions being in oligodendroglia whilst others in astrocytes.
Nevertheless, the authors noted that characteristic PSP type ‘tufted astrocytes’ were not
observed [18]. Although the accurate nosological classification of this case was restricted by
its limited brain sampling, Molina et al. [18] concluded that their case could not be “ascribed
to one of the nosological entities characterised by glial inclusions, like MSA and PSP”.
Despite the GCIs in this case being described as both phospho-tau and Gallyas positive, the
relative frequency of the different morphological types and their respective staining
properties were not reported.
In 2001, Bigio et al. [3] provided the first detailed pathological, ultrastructural and
biochemical assessment of a single case with sporadic frontotemporal dementia (FTD) and
severe neurodegeneration in the frontal and temporal lobes associated with “distinctive
globular neuronal and glial, tau-positive inclusions in grey and white matter”. The GGIs
occurred predominantly in oligodendrocytes and were accompanied by “rare tufted
astrocyte-like glial inclusions”. Despite the latter being characteristic of PSP, neuronal loss
in subcortical nuclei affected in PSP was only mild. The distribution of pathology,
predominance of 4R tau isoforms and susceptibility of oligodendrocytes were noted as being
similar to those seen in a familial form of frontotemporal lobar degeneration with MAPT
mutation (FTLD–MAPT). This had previously been termed “familial multiple system
tauopathy with presenile dementia” (MSTD) and shown to be associated with an exon 10+3
intronic mutation [22, 23]. Due to presumed neuropathological and biochemical similarities
with this familial disorder and the absence of MAPT mutations, Bigio et al. [3] classified
their case as “sporadic multiple system tauopathy with dementia” (sporadic MSTD). It is of
note that in hindsight the morphology of GGIs described by Bigio et al. [3] appears distinct
from the coiled body-type inclusions seen in familial MSTD [22, 24].
Globular glial inclusions (GGIs) were subsequently reported in additional single case reports
[2, 6, 21]. In one of them “leukoencephalopathy” was emphasised due to the severe white
matter damage and oligodendroglial cell loss related to extensive tau pathology in the white
matter [21], while another, on the basis of morphological similarities to the case described
by Bigio et al. [3], used the term “multiple system tauopathy” [6]. One case report of FTD,
described as an “atypical tauopathy”, emphasised prominent white matter involvement with
widespread oligodendroglial tau immunoreactivity although described as coiled bodies and
not GGIs [10].
In 2006, Josephs et al. [12] described 12 cases in which GGIs were also a morphological
feature. In contrast to the above-discussed sporadic MSTD cases presenting as FTD, their
cases had clinical evidence of upper motor neuron disease plus extrapyramidal features
leading to a number of clinical diagnoses including PSP, primary lateral sclerosis (PLS) and
corticobasal syndrome (CBS). Neuropathologically, the cases demonstrated circumscribed
Ahmed et al. Page 3













cortical atrophy, which was marked in the superior frontal gyrus, mild in the superior
parietal lobule and also affected the precentral gyrus. Microscopically there was superficial
spongiosis and neuronal loss, which were most severe in the motor cortex, along with
damage to the underlying white matter and prominent corticospinal tract degeneration
(CST), a distribution of pathology not reported in the sporadic MSTD. GGIs occurred
predominantly as “globular oligodendroglial inclusions” (GOIs) and were accompanied by
morphological lesions typically found in PSP, such as frequent coiled bodies and fewer
tufted astrocytes. It is of note that in contrast to PSP, tufted astrocytes were mostly Gallyas-
negative and subcortical nuclei severely affected in PSP were only mildly involved. For
these reasons, Josephs et al. [12] classified their cases as “atypical PSP with corticospinal
tract degeneration” (PSP–CST).
In 2008, Kovacs et al. [13] reported the first systematic and comprehensive
clinicopathological assessment of a series of seven cases with GGIs, which they termed
“white matter tauopathy with globular glial inclusions” (WMT–GGI). Clinically, their cases
were compatible with the behavioural variant of FTD and were histologically reminiscent of
the sporadic MSTD case described by Bigio et al. [3], albeit the density of GGIs particularly
in the white matter was much greater [13]. GGIs were predominantly found in
oligodendrocytes. In addition, rare coiled bodies were also present. similar to the original
sporadic MSTD case [3], “tufted astrocyte-like” inclusions were also identified in the
affected grey-matter structures, described as having “dot-like immunopositivity in the
proximal segments of branching processes, with a star-like appearance”. Like those
described by Josephs et al. [12] these were “non-argyrophilic” (negative with Gallyas silver-
staining), although rare PSP-type Gallyas-positive tufted astrocytes were also observed.
Biochemical examination, performed in two cases, supported the immunohistochemical
observation indicating that this is a predominantly 4R-tauopathy. Kovacs et al. [13] also
conducted an exhaustive review of the literature and were the first to suggest that sporadic
tauopathies with GGIs were “a distinct neuropathological entity associated with sporadic
FTLD”. They also noted that beyond the synucleinopathy MSA, tauopathies with GGIs
extend the group of neurodegenerative disorders with a prominent oligodendroglial
pathology.
In 2010, Fu et al. [7] published three cases under the term of “sporadic 4R tauopathy with
frontotemporal lobar degeneration, parkinsonism and motor neuron disease” (FTLD–P–
MND). Tau immunostaining identified numerous “coiled body-like lesions”, which in
retrospect were consistent with GOIs. Frequent tau-positive astrocytes also had a globular
appearance and similar to some of the cases described above [12, 13], were shown to be
mostly Gallyas-negative [7]. The distribution of pathology was similar to that seen in PSP–
CST like cases [12] with severe degeneration of the motor cortex and corticospinal tract, but
with the added involvement of lower motor neurons [7]. There were also similarities to
sporadic MSTD with two of their cases showing significant frontotemporal atrophy and
frontal atrophy in the third. Biochemical analysis revealed not only 68 and 64 kDa bands
characteristic of 4R-tauopathies, but also a weaker ~33 kDa lower-molecular-weight species
[7] that is reported to be more prominent in PSP [27]. Fu et al. [7] acknowledged the overlap
with PSP–CST and sporadic MSTD, but concluded that the severity of the tau-positive
astrocytic pathology and its lack of Gallyas staining, together with the overall distribution of
pathology, were features inconsistent with known neuropathological disorders.
Most recently, Ahmed et al. [1] performed for the first time a comparative
clinicopathological and biochemical study of two cases with GGIs representing two
subtypes: MSTD and PSP–CST. There were many similarities between their two cases: (1)
specific cortical areas and their associated descending white matter tracts were severely
affected, (2) neurodegeneration in subcortical nuclei typically affected in PSP was only
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mild, (3) tau-positive GOIs were prominent and characteristic features, (4) a mixture of large
GOIs and typical coiled bodies were present, (5) tau-positive astrocytes were a prominent
feature, with many having a globular morphology (termed GAI), (6) tau-positive astrocytic
inclusions were mostly Gallyas-negative and (7) biochemical analysis of tau protein
revealed not only strong bands at 68 and 64 kDa, but also weaker lower-molecular-weight
bands, with a ~35 kDa band. Some of the differences between their two cases were related to
the severity and distribution of lesions, which could explain the different clinical
presentations. In addition, the GOIs in their sporadic MSTD case were generally larger and
more apparently globular than those found in their PSP–CST case. Furthermore, typical
coiled bodies were more common in the latter and some even had an intermediate-type
morphology as such oligodendroglial inclusions were larger, yet retained an overall coiled
body-type appearance. With these similarities and differences in mind, Ahmed et al. [1]
suggested that their cases were variants representing the spectrum of a single distinct disease
entity; a notion first suggested by Kovacs et al. [13]. As in FTLD–TDP [15] and FTLD–FUS
[14], the clinical spectrum (illustrated in Fig. 2) is defined by motor neuron disease at one
end and FTD at the other, with or without extrapyramidal features [1]. As GGIs were a
consistent and defining feature of sporadic MSTD, PSP–CST and FTLD–P–MND cases
Ahmed et al. [1] proposed the collective term globular glial tauopathy (GGT) to encompass
these cases.
Difficulties in the classification of cases with GGIs
Since the first report in 1998, at least 30 individual cases have been reported with GGIs
being a characteristic feature (Supplementary Table 1) [1–3, 6, 10, 12, 13, 18, 20, 21]. It is
of note that the distinctive glial lesions seen in these cases have been described under a
number of terms such as GCIs [18], GGIs [3, 13], GOIs [1, 12], coiled bodies [7, 10], tufted
astrocytes [3, 12], globular astrocytes [1] or just tau-positive astrocytes [7]. Many of the
authors have noted diagnostic difficulties in assigning their respective cases to well-
established entities, such as PSP, with which the published cases share some clinical,
neuropathological and biochemical features. This also explains why various, novel terms
were used to classify such cases, including “sporadic MSTD” [3], a form of
“leukoencephalopathy” [21], “atypical tauopathy” [10], WMT–GGI [13], PSP–CST [12]
and FTLD–P–MND [7]. Subsequently some confusion has arisen from using terms such as
sporadic MSTD, which is morphologically different from the previously described familial
MSTD (see also above). Similarly, the term PSP–CST might be diagnostically confusing
given that not all cases presented with a PSP syndrome and some of the cardinal
neuropathological features of PSP are also missing, such as the significant involvement of
subcortical nuclei and the absence of Gallyas-positive tufted astrocytes. Even when the
existence of cases with GGIs has been acknowledged in the literature, there have been
confusion and redundancy in their classification as demonstrated by the recent FTLD
guidelines, which included sporadic MSTD and WMT–GGI as separate FTLD-tau subtypes
[17].
The lack of consistent terminology for cases with GGIs and a trend to classify
neurodegenerative diseases based on molecular neuropathology prompted Ahmed et al. [1]
to propose GGT as an encompassing term for cases with GGIs, followed by a sub-
stratification strategy based on the regional distribution and severity of neurodegeneration,
hoping that this would pave the way for a formal consensus agreement on the
neuropathological terminology of these rare 4R tauopathies.
Ahmed et al. Page 5














To address some of the problems stated above, the authors of this report (led by G.G.K.)
initiated a study to reach a consensus on the classification of this group of 4R-tauopathy.
Microscopic images (6–10 per case) of tau immunostained sections and their corresponding
publication were provided by the authors of previously reported cases [1–3, 6, 10, 12, 13,
20]. Microscopic images from a total of 22 individual cases with suspected GGIs were sent
to participants (authors of this report; n = 16), who were each asked if (1) GOIs were indeed
present, (2) coiled body-type inclusions were also present, (3) any astrocytic tau pathology
was different to typical PSP tufted astrocytes, (4) the white matter or grey matter was
predominately affected by tau pathology, (5) the cases represent a single neuropathological
entity and (6) the cases could be separated into distinct subgroups? A majority was defined
as 80 % or more of the participants in agreement.
The majority of participants agreed that (1) GOIs were present in every case, including those
where GOIs were detected after reevaluation [10, 20]; (2) coiled body inclusions were
present in all the PSP–CST and FTLD–P–MND-type cases, whereas they were variably
present in the sporadic MSTD cases; (3) the morphology of astrocytic tau inclusions was
different from, but may overlap with, tufted astrocytes; (4) the white matter was more
affected in the MSTD-type cases, whereas in other cases there was either more grey matter
or equal grey vs. white matter involvement; (5) these cases are likely to represent a single
disease entity; and (6) the cases could be separated into distinct clinicopathological
subgroups. some participants also commented that Gallyas silver staining might be an
efficient method to establish differences in astrocytic tau pathology and that the astrocytic
and oligodendroglial inclusions in some cases might have a multi-globular morphology with
the relative frequency of these glial inclusions differing between cases. Based on this
heterogeneity, the majority of participants suggested that at least three subtypes exist, which
are described in Table 1.
Future classification and nosology
In summary, the neuropathological hallmarks of these cases that allow them to be
distinguished from other members of the 4R-tauopathy family are the globular nature of
both oligodendroglial and astrocytic inclusions, termed GGIs (Fig. 1). As the severity of
oligodendroglial and astrocytic GGI pathologies can be different within a case, the former
could be termed GOIs and the latter, GAIs. GOIs are defined as globular structures the size
of, or larger than the nucleus of the cell [13] and can be variably accompanied by typical
coiled bodies [1]. GAIs are defined as distinct globular or dot-like structures of variable size
seen in the cytoplasm or processes of astrocytes. They are mostly non-argyrophilic,
indicating a non-fully fibrillar conformation of tau, and might be accompanied by astrocytic
inclusions that are morphologically indistinguishable from PSP-type tufted astrocytes;
however, like GAIs these tufted astrocyte-like lesions are rarely Gallyas positive. In
contrast, GOIs and coiled bodies are consistently Gallyas positive [1, 13].
Based on these characteristics and the trend to classify neurodegenerative diseases based on
molecular neuropathology [16, 17], in 2011 Ahmed et al. [1] have proposed the term GGT.
This terminology could be followed by a sub-stratification strategy (Fig. 2); accordingly
cases with predominantly fronto-temporal and without corticospinal involvement (i.e.
sporadic MSTD-type cases) would be termed GGT Type I, whereas cases with
predominately motor cortex and corticospinal tract degeneration (i.e. PSP–CST type cases)
would be classified as GGT Type II. Those with fronto-temporal, motor cortex and
corticospinal tract involvement (i.e. those previously termed FTLD–P–MND) would be
classified as GGT Type III. This reflects different selective vulnerability, since the
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distribution of GGIs clearly correlates with the predominant clinical symptoms [1, 7, 12,
13]. The authors of this study support this neuropathology-based classification strategy,
which is complemented by the presence and predominance of GOIs and GAIs as well as the
presence or absence of upper and lower motor neuron involvement (Table 1) and would
allow for phenotypic grouping, account for the heterogeneity within this group and avoid
confusion or redundancy in terminology. This study has stopped short of proposing specific
neuropathological diagnostic criteria for GGT and its subtypes, but increased recognition
and correct classification of these cases, aided by the proposed classification strategy, should
provide a big enough sample size to formulate such criteria in the near future. Due to the
overlapping neuropathological features of the different GGT subtypes it is likely that future
criteria for the subtypes will be based on the regional distribution and severity of lesions and
neurodegeneration, in a similar fashion to the way olivopontocerebellar and striatonigral
subtypes of MSA are currently distinguished [19]. The previous reports of GGT-type cases
[1–3, 6, 10, 12, 13, 20], the majority of which is single case reports, suggest that GGT cases
are relatively rare and that sub-typing a rare disorder without fully appreciating its
neuropathological heterogeneity might be premature. Nevertheless, the classification
strategy that we have proposed (Fig. 2) has the flexibility to incorporate any additional sub-
types of GGT that are likely to be discovered in the future.
In comparison with other 4R-tauopathies (Table 2), GGT is most closely associated with
PSP owing to similarities in astrocytic inclusion morphology and tau biochemical signature
(68, 64 and ~35 kDa bands). In addition to the morphological differences between GOI and
typical coiled bodies (Fig. 1), the use of Gallyas silver-staining [8] could prove instrumental
as a diagnostic tool to help distinguish GGT from PSP, especially in the evaluation of
astrocytic pathology, although occasional Gallyas-positive tufted astrocyte-like inclusions
may be noted in GGT cases as well. The neuropathological features of GGT should be easily
distinguishable from those of CBD and AGD [5, 25]; however, this is not the case for
FTLD–MAPT, which can share neuropathological and biochemical similarities with GGT
[9, 11] (Table 2). For these reasons, suspected GGT cases should be routinely sent for
MAPT genetic analysis to exclude the diagnosis of FTLD–MAPT. In 25 of the 30 cases
reviewed in this paper, information about MAPT genetic analysis was available and in none
of the cases was a mutation identified (supplementary Table 1).
Conclusion
Presenting with a combination of FTD, MND and/or extrapyramidal features, GGTs belong
to the family of the 4R-tauopathies. GGTs are characterised neuropathologically by tau-
positive GOIs and GAIs, the latter of which are mostly Gallyas-negative. These
characteristic features help GGT to be distinguished from other 4R-tauopathies, in particular
PSP. Whether the neuropathological subtypes of GGT are distinct disease entities or part of
a spectrum of disease is open to a similar debate that has been on-going for PSP and CBD
[5]. The severe involvement of oligodendroglia and resulting white matter changes (myelin
pallor, axonal loss and gliosis) suggests that GGT expands the spectrum of primary
oligodendrogliopathies. As has been suggested for the oligodendroglial inclusions of MSA
[26], GGIs may play a central role in the pathogenesis of GGT. The combination of white
matter changes and the deposition of predominantly 4R tau isoforms could be exploited in
the future using neuroimaging techniques and CSF protein analysis (respectively), for the
detection and diagnosis of GGT during life. The aim of reviewing 30 historical cases
classified as GGT was to draw attention to their existence and to help improve the
nomenclature used to describe them. Improving the detection and correct classification of
GGT cases in the future should increase the number of cases available for retrospective
clinicopathological char-acterisation, which will hopefully pave the way for establishing
clinical and neuropathological diagnostic research criteria.
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Comparison of oligodendroglial and astrocytic inclusions found in GGT and PSP
Comparison of oligodendroglial and astrocytic inclusions and distribution of tau pathology
in the grey matter (temporal cortex for cases representing Type I and PSP and motor cortex
for cases representing Type II and III) and white matter (underlying white matter of the
representative cortical areas) in representative cases of GGT types and PSP. Scale bar
represents 10 μm in the images for oligodendrocytes and astrocytes and 100 μm for the
overview images of the grey and white matter. Immunostaining is specific for
phosphorylated-tau (AT8)
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Classification strategy for GGT in relation to other commonly recognised 4R-tauopathies.
Abbreviations: CBD corticobasal degeneration, PSP progressive supranuclear palsy, GGT
globular glial tauopathies, FTLD-MAPT frontotemporal lobar degeneration with MAPT
mutation, AGD argyrophilic grains disease, MND motor neuron disease features, FTD
frontotemporal dementia
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Table 1





GOIs CBs GAIs AHC Clinical features Common clinical diagnoses Previous reports
Type I FT +++ + + - FLF and/or Dem FTD, PiD [1-3, 6, 10, 13, 18,
21]
Type II MTR and/or CST ++ ++ + ± FLF, PF and/or
EPF
PSP, CBS, MND, PLS [1, 12]
Type III FT, MTR and/or
CST
++ ++ +++ ++ FLF, Dem, MND
and/or EPF
PSP, CBS, MND [7, 20]
GOIs globular oligodendroglial inclusions, CBs coiled body-type inclusions, GAIs globular astrocytic inclusion, AHC anterior horn cell
involvement (neuronal loss and tau pathology), FT frontotemporal, FLF frontal-lobe features, Dem dementia, FTD frontotemporal dementia, PiD
Pick's disease, MTR motor cortex, CST corticospinal tract, PF pyramidal features, EPF extrapyramidal features, PSP progressive supranuclear
palsy, CBS corticobasal syndrome, PLS primary lateral sclerosis, MND motor neuron disease features, - negative/absent, + low severity, ++
moderate severity, +++ high severity
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Table 2
Comparison of GGT and other commonly recognised 4R-tauopathies
Pathological and biochemical features Has this feature been documented in this particular disorder?
GGT PSP CBD AGD FTLD-MAPT
Neuronal tau inclusions
a Y Y Y Y Y
Oligodendroglial tau inclusions
a Y Y Y Y Y
Coiled body inclusions 
b N Y Y Y Y
Globular oligodendroglial inclusions 
b Y N N N
Y
d
Gallyas-positive oligodendroglial inclusions Y Y Y Y Y
Astrocytic tau inclusions
a Y Y Y Y Y
Tufted astrocytes
Y
c Y N N Y
Astrocytic plaques N N Y N Y
Gallyas-positive astrocytic inclusions 
b N Y Y Y Y
4R tau isoforms deposited
b Y Y Y Y Y
68 and 64 kDa tau bands Y Y Y Y Y
35 kDa tau band 
b Y Y N
-
e Y
GGT globular glial tauopathies, PSP progressive supranuclear palsy, CBD corticobasal degeneration, AGD argyrophilic grains disease, FTLD-
MAPT frontotemporal lobar degeneration with MAPT mutation, 4R 4-repeat
a




Astrocytic inclusions may be indistinguishable from tufted astrocytes based on morphology alone
d
Oligodendroglial inclusions with a globular morphology, described as “stout coiled bodies”, have been reported in FTLD-MAPT [11]
e
Unknown
Acta Neuropathol. Author manuscript; available in PMC 2014 February 05.
